Mesoblast Named 2016 Cell Therapy Company of the Year at Frost & Sullivan Asia Pacific Best Practices Awards
October 18 2016 - 6:00AM
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it
received the Frost & Sullivan Asia Pacific 2016 Cell
Therapy Company of the Year Award. The Frost & Sullivan
Awards identify and honor the best-in-class companies that
have demonstrated excellence in their industry.
According to Rhenu Bhuller, Senior Vice
President & Partner, Transformational Health, Frost &
Sullivan, Mesoblast’s strong overall performance and its
achievements throughout the last financial year had earned the 2016
award.
“This award recognizes Mesoblast's global
achievements and its focus on clinical development of innovative
cellular medicines in under-served therapy areas such as
cardiovascular and degenerative diseases," she said.
"Cell therapy will revolutionize how patients
will be medicated in the future in areas with high unmet need such
as cardiovascular and oncology among others. An increasing number
of late-stage hybrid therapies such as cell-gene or stem cell-gene
therapies are promising and can hit the mainstream market, which
Frost & Sullivan projects to reach US$10 billion by 2020."
The selection of this award was based on
interviews, primary market analysis and extensive secondary
research conducted by Frost & Sullivan's industry analyst team.
Key criteria used were visionary innovation and performance;
addressing unmet needs; visionary scenarios through mega trends;
implementation of best practices; blue ocean strategy; impact;
price/performance value and brand equity. The Award is made to the
company that received the number one industry rank.
Previously, the Mesoblast Group received the
2009 Frost & Sullivan North America Emerging Company Award in
the Soft Tissue Repair Market, and the 2008 Frost & Sullivan
United States Stem Cell Market Technology Innovation of the
Year.
About Frost & SullivanFrost
& Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth,
innovation and leadership. Frost & Sullivan leverages over 50
years of experience in partnering with Global 1000 companies,
emerging businesses and the investment community from more than 40
offices on six continents. www.frost.com
Frost & Sullivan’s Best Practices Awards
recognize companies throughout a range of regional and global
markets for superior leadership, technological innovation, customer
service, and strategic product development. Frost & Sullivan's
industry analyst team benchmarks market participants and measures
their performance through independent, primary interviews, and
secondary industry research in order to evaluate and identify best
practices.
About MesoblastMesoblast
Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing
innovative cell-based medicines. The Company has leveraged its
proprietary technology platform, which is based on specialized
cells known as mesenchymal lineage adult stem cells, to establish a
broad portfolio of late-stage product candidates. Mesoblast’s
allogeneic, ‘off-the-shelf’ cell product candidates target advanced
stages of diseases with high, unmet medical needs including
cardiovascular diseases, immune-mediated and inflammatory
disorders, orthopedic disorders, and oncologic/hematologic
conditions.
Forward-Looking StatementsThis
press release includes forward-looking statements that relate to
future events or our future financial performance and involve known
and unknown risks, uncertainties and other factors that may cause
our actual results, levels of activity, performance or achievements
to differ materially from any future results, levels of activity,
performance or achievements expressed or implied by these
forward-looking statements. We make such forward-looking statements
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
Forward-looking statements should not be read as a guarantee of
future performance or results, and actual results may differ from
the results anticipated in these forward-looking statements, and
the differences may be material and adverse. You should read this
press release together with our risk factors, in our most recently
filed reports with the SEC or on our website. Uncertainties and
risks that may cause Mesoblast's actual results, performance or
achievements to be materially different from those which may be
expressed or implied by such statements, and accordingly, you
should not place undue reliance on these forward-looking
statements. We do not undertake any obligations to publicly update
or revise any forward-looking statements, whether as a result of
new information, future developments or otherwise.
For further information, please contact:
Julie Meldrum
Corporate Communications, Mesoblast
T: +61 3 9639 6036
E: julie.meldrum@mesoblast.com
Schond Greenway
Investor Relations, Mesoblast
T: +1 212 880 2060
E: schond.greenway@mesoblast.com
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mesoblast (NASDAQ:MESO)
Historical Stock Chart
From Apr 2023 to Apr 2024